CureSearch is pleased to announce the appointment of John Polson, Chairman and Managing Partner of Fisher Phillips, to our Board of Directors.
CureSearch for Children’s Cancer Welcomes John Polson to Board of Directors Read More »
We’re thrilled to celebrate Frank Gioscia, a longtime Ultimate Hike champion, who has officially surpassed $500,000 in lifetime fundraising—a milestone that makes him Ultimate Hike’s top fundraiser of all time!
Ultimate Hiker Frank Gioscia raises $500K for Childhood Cancer Research Read More »
For most families, childhood cancer is unfathomable. But for families like Luke Getchell’s, childhood cancer is their heartbreaking, stomach-turning reality. In July of 2018, 13-year-old Luke was diagnosed with acute myeloid leukemia (AML) with a common genetic alteration, FLT3-ITD. That
Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions and mutations. Last week, on April 23, 2024, Day One Biopharmaceuticals was granted Accelerated
The urgent need for advanced childhood brain cancer research G34R-mutant pediatric diffuse glioma, a devastating brain cancer affecting children and young adults, poses significant challenges in treatment due to its aggressive nature, limited therapeutic options, and the long-term side effects.
This Pediatric Glioma has no known cure. Dr. Breunig is Taking on the Challenge. Read More »
Neuroblastoma is the most common extracranial solid tumor of childhood arising within the developing nervous system. Approximately half of neuroblastoma patients are diagnosed with high-risk disease, which is especially aggressive with a 50% survival rate. If a child’s high-risk neuroblastoma
Acute Myeloid leukemia (AML) is the second most common leukemia in children, and the prognosis after relapse is poor. Unlike current CAR T treatment for the most common childhood leukemia, acute lymphoblastic leukemia (ALL), patients with AML experience significant toxicity
Dr. Moghimi is developing next-generation CAR T-cells to treat pediatric AML. Read More »
As an infant, Lindsey Grubbs did what most babies do. She played, she napped, she cried, but she was dealing with something far from normal. “I was a baby, so of course I didn’t fully know what was happening
Clinical trial aims to bring new therapies to childhood brain tumors with low survival rates Bethesda, Md. – April 3, 2023 – CureSearch for Children’s Cancer, a national nonprofit on a mission to end childhood cancer by driving targeted and
CureSearch to fund Phase I clinical trial for pediatric brain cancer Read More »
“We were fortunate that CureSearch had just launched their Catapult Award program….It enabled researchers to access up to $2.5M in funding over three years, through a streamlined application process, rather than contending with multiple applications for smaller grants which would have lengthened
